Advisory Council on Alzheimer's Research, Care, and Services; Meeting, 34242-34243 [2021-13851]
Download as PDF
34242
Federal Register / Vol. 86, No. 122 / Tuesday, June 29, 2021 / Notices
in determining the scope and content of
the environmental analysis.
Russell Larson,
Director, Portfolio Management Division,
Pacific Rim Region, Public Buildings Service.
[FR Doc. 2021–13828 Filed 6–28–21; 8:45 am]
GENERAL SERVICES
ADMINISTRATION
[OMB Control No. 3090–0080; Docket No.
2021–0001; Sequence No. 3]
Submission for OMB Review; General
Services Administration Acquisition
Regulation; Contract Financing Final
Payment, GSA Form 1142, Release of
Claims
Office of Acquisition Policy,
General Services Administration (GSA).
ACTION: Notice of request for public
comments regarding an extension to an
existing OMB clearance.
AGENCY:
Under the provisions of the
Paperwork Reduction Act, the
Regulatory Secretariat Division will be
submitting to the Office of Management
and Budget (OMB) a request to review
and approve an extension of a
previously approved information
collection requirement of GSA Form
1142, Release of Claims, regarding final
payment under construction and
building services contract.
DATES: Submit comments on or before:
July 29, 2021.
ADDRESSES: Written comments and
recommendations for this information
collection should be sent within 30 days
of publication of this notice to
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function.
FOR FURTHER INFORMATION CONTACT:
Bryon Boyer, Procurement Analyst,
Office of Governmentwide Policy, by
phone at 817–850–5580 or by email at
gsarpolicy@gsa.gov.
SUPPLEMENTARY INFORMATION:
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
A. Purpose
The General Services Administration
Acquisition Regulation (GSAR) clause
552.232–72 requires construction and
building services contractors to submit
a release of claims before final payment
is made to ensure contractors are paid
in accordance with their contract
requirements and for work performed.
GSA Form 1142, Release of Claims is
used to achieve uniformity and
consistency in the release of claims
process.
18:06 Jun 28, 2021
Respondents: 1,330.
Responses per Respondent: 1.
Annual Responses: 1,330.
Hours per Response: 0.10.
Total Burden Hours: 133.
C. Public Comments
BILLING CODE 6820–YF–P
VerDate Sep<11>2014
B. Annual Reporting Burden
Jkt 253001
A notice published in the Federal
Register at 86 FR 20159 on April 16,
2021. No comments were received.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the Regulatory Secretariat Division by
calling 202–501–4755 or emailing
GSARegSec@gsa.gov. Please cite OMB
Control No. 3090–0080; Contract
Financing Final Payment, GSA Form
1142, Release of Claims, in all
correspondence.
Jeffrey A. Koses,
Senior Procurement Executive, Office of
Acquisition Policy, Office of Governmentwide Policy.
[FR Doc. 2021–13808 Filed 6–28–21; 8:45 am]
BILLING CODE 6820–61–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Council on Alzheimer’s
Research, Care, and Services; Meeting
Assistant Secretary for
Planning and Evaluation, HHS.
ACTION: Notice of meeting.
AGENCY:
This notice announces the
public meeting of the Advisory Council
on Alzheimer’s Research, Care, and
Services (Advisory Council). The
Advisory Council provides advice on
how to prevent or reduce the burden of
Alzheimer’s disease and related
dementias on people with the disease
and their caregivers. During the July 19,
2021 meeting the Advisory Council will
discuss the implications of and
opportunities presented by the approval
of aducanumab. The Council will also
hear updates from federal workgroups
on efforts undertaken in the last quarter.
The risk reduction subcommittee will
present a summary of their work and
recommendations. The research, clinical
care, and long-term services and
supports subcommittees will present
recommendations and the Council will
vote on adopting them.
DATES: The meeting will be held on July
19, 2021 from 12:30 p.m. to 4:30 p.m.
EST.
ADDRESSES: The meeting will be virtual,
streaming live at www.hhs.gov/live.
Comments: Time is allocated on the
agenda to hear public comments from
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
4:00 p.m. to 4:30 p.m. The time for oral
comments will be limited to two (2)
minutes per individual. In order to
provide a public comment, please
register by emailing your name to
napa@hhs.gov by Thursday, July 15. On
Friday, July 16, registered commenters
will receive both a dial-in number and
a link to join the meeting virtually;
individuals will have the choice to
either join virtually via the link, or to
call in only by using the dial-in number.
Note: There may be a 30–45 second
delay in the livestream video
presentation of the conference. For this
reason, if you have pre-registered to
submit a public comment, it is
important to connect to the meeting by
3:45 p.m. to ensure that you do not miss
your name and allotted time when
called. If you miss your name and
allotted time to speak, you may not be
able to make your public comment. All
participant audio lines will be muted for
the duration of the meeting and only
unmuted by the Host at the time of the
participant’s public comment. Should
you have questions during the session
email napa@hhs.gov and someone will
respond to your message as quickly as
possible.
In order to ensure accuracy, please
submit a written copy of oral comments
for the record by emailing napa@
hhs.gov by Tuesday, July 20. These
comments will be shared on the website
and reflected in the meeting minutes.
In lieu of oral comments, formal
written comments may be submitted for
the record by Tuesday, July 20 to Helen
Lamont, Ph.D., OASPE, 200
Independence Avenue SW, Room 424E,
Washington, DC 20201. Comments may
also be sent to napa@hhs.gov. Those
submitting written comments should
identify themselves and any relevant
organizational affiliations.
FOR FURTHER INFORMATION CONTACT:
Helen Lamont, 202–260–6075,
helen.lamont@hhs.gov. Note: The
meeting will be available to the public
live at www.hhs.gov/live.
SUPPLEMENTARY INFORMATION: Notice of
these meetings is given under the
Federal Advisory Committee Act (5
U.S.C. App. 2, section 10(a)(1) and
(a)(2)). Topics of the Meeting:
Aducanumab, dementia risk reduction,
recommendations.
Procedure and Agenda: The meeting
will be webcast at www.hhs.gov/live and
video recordings will be added to the
National Alzheimer’s Project Act
website when available, after the
meeting.
Authority: 42 U.S.C. 11225; Section 2(e)(3)
of the National Alzheimer’s Project Act. The
panel is governed by provisions of Public
E:\FR\FM\29JNN1.SGM
29JNN1
Federal Register / Vol. 86, No. 122 / Tuesday, June 29, 2021 / Notices
Law 92–463, as amended (5 U.S.C. Appendix
2), which sets forth standards for the
formation and use of advisory committees.
Dated: June 17, 2021.
Rebecca Haffajee,
Acting Assistant Secretary for Planning and
Evaluation.
[FR Doc. 2021–13851 Filed 6–28–21; 8:45 am]
BILLING CODE 4150–05–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Review of Outstanding New
Environmental Scientist Program.
Date: July 12, 2021.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Durham, NC 27709 (Virtual
Meeting).
Contact Person: Laura A., Thomas, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, National Institute of Environmental
Health Sciences, Research Triangle Park, NC
27709, 984–287–3328, laura.thomas@
nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; NIH Pathway to
Independence Award (K99/R00).
Date: July 14, 2021.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Durham, NC 27709 (Virtual
Meeting).
Contact Person: Varsha Shukla, Ph.D.,
Scientific Review Branch, Division of
Extramural Research and Training, National
Institute of Environmental Health Science,
VerDate Sep<11>2014
18:06 Jun 28, 2021
Jkt 253001
530 Davis Dr., Keystone Bldg., Room 3094,
Durham, NC 27713, 984–287–3288,
Varsha.shukla@nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Educational Careers in
Environmental Health and Toxicology.
Date: July 15, 2021.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Durham, NC 27709 (Virtual
Meeting).
Contact Person: Alfonso R. Latoni, Ph.D.,
Chief and Scientific Review Officer,
Scientific Review Branch, Division of
Extramural Research and Training, National
Institute of Environmental Health Sciences,
Research Triangle Park, NC 27709, 984–287–
3279, alfonso.latoni@nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; NIEHS Summer Research
Education Experience Program.
Date: July 16, 2021.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Durham, NC 27709 (Virtual
Meeting).
Contact Person: Linda K. Bass, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat’l Institute Environmental
Health Sciences, P.O. Box 12233, MD EC–30,
Research Triangle Park, NC 27709, 984–287–
3236, bass@niehs.nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Machine Learning
Application in the Environmental Health
Sciences—Phase I SBIR Review.
Date: July 20, 2021.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Durham, NC 27709 (Virtual
Meeting).
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental,
Health Sciences, P.O. Box 12233, MD EC–30/
Room 3171, Research Triangle Park, NC
27709, 984–287–3340, worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
34243
Dated: June 23, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–13766 Filed 6–28–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Health Promotion and Clinical Care
Management Research.
Date: July 20, 2021.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Wenjuan Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 3154,
Bethesda, MD 20892, (301) 480–8667,
wangw22@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel
Hepatobiliary Pathophysiology and
Toxicology.
Date: July 21, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Ganesan Ramesh, Ph.D.,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 2182, MSC 7818, Bethesda, MD 20892,
(301) 827–5467, ganesan.ramesh@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel PAR Panel:
Pediatric and Obstetric Pharmacology and
Therapeutics.
Date: July 23, 2021.
Time: 10:00 a.m. to 5:00 p.m.
E:\FR\FM\29JNN1.SGM
29JNN1
Agencies
[Federal Register Volume 86, Number 122 (Tuesday, June 29, 2021)]
[Notices]
[Pages 34242-34243]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-13851]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Council on Alzheimer's Research, Care, and Services;
Meeting
AGENCY: Assistant Secretary for Planning and Evaluation, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: This notice announces the public meeting of the Advisory
Council on Alzheimer's Research, Care, and Services (Advisory Council).
The Advisory Council provides advice on how to prevent or reduce the
burden of Alzheimer's disease and related dementias on people with the
disease and their caregivers. During the July 19, 2021 meeting the
Advisory Council will discuss the implications of and opportunities
presented by the approval of aducanumab. The Council will also hear
updates from federal workgroups on efforts undertaken in the last
quarter. The risk reduction subcommittee will present a summary of
their work and recommendations. The research, clinical care, and long-
term services and supports subcommittees will present recommendations
and the Council will vote on adopting them.
DATES: The meeting will be held on July 19, 2021 from 12:30 p.m. to
4:30 p.m. EST.
ADDRESSES: The meeting will be virtual, streaming live at www.hhs.gov/live.
Comments: Time is allocated on the agenda to hear public comments
from 4:00 p.m. to 4:30 p.m. The time for oral comments will be limited
to two (2) minutes per individual. In order to provide a public
comment, please register by emailing your name to [email protected] by
Thursday, July 15. On Friday, July 16, registered commenters will
receive both a dial-in number and a link to join the meeting virtually;
individuals will have the choice to either join virtually via the link,
or to call in only by using the dial-in number. Note: There may be a
30-45 second delay in the livestream video presentation of the
conference. For this reason, if you have pre-registered to submit a
public comment, it is important to connect to the meeting by 3:45 p.m.
to ensure that you do not miss your name and allotted time when called.
If you miss your name and allotted time to speak, you may not be able
to make your public comment. All participant audio lines will be muted
for the duration of the meeting and only unmuted by the Host at the
time of the participant's public comment. Should you have questions
during the session email [email protected] and someone will respond to your
message as quickly as possible.
In order to ensure accuracy, please submit a written copy of oral
comments for the record by emailing [email protected] by Tuesday, July 20.
These comments will be shared on the website and reflected in the
meeting minutes.
In lieu of oral comments, formal written comments may be submitted
for the record by Tuesday, July 20 to Helen Lamont, Ph.D., OASPE, 200
Independence Avenue SW, Room 424E, Washington, DC 20201. Comments may
also be sent to [email protected]. Those submitting written comments should
identify themselves and any relevant organizational affiliations.
FOR FURTHER INFORMATION CONTACT: Helen Lamont, 202-260-6075,
[email protected]. Note: The meeting will be available to the public
live at www.hhs.gov/live.
SUPPLEMENTARY INFORMATION: Notice of these meetings is given under the
Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and
(a)(2)). Topics of the Meeting: Aducanumab, dementia risk reduction,
recommendations.
Procedure and Agenda: The meeting will be webcast at www.hhs.gov/live and video recordings will be added to the National Alzheimer's
Project Act website when available, after the meeting.
Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National
Alzheimer's Project Act. The panel is governed by provisions of
Public
[[Page 34243]]
Law 92-463, as amended (5 U.S.C. Appendix 2), which sets forth
standards for the formation and use of advisory committees.
Dated: June 17, 2021.
Rebecca Haffajee,
Acting Assistant Secretary for Planning and Evaluation.
[FR Doc. 2021-13851 Filed 6-28-21; 8:45 am]
BILLING CODE 4150-05-P